Nonalcoholic Steatohepatitis (NASH)
Nonalcoholic steatohepatitis (NASH) is a condition where fat buildup in the liver leads to liver inflammation and damage. Progression of NASH can cause liver hardening (fibrosis) and scarring (cirrhosis).
Nonalcoholic Steatohepatitis (NASH) falls under theLiver Healthcategory.
Last Updated:October 13, 2024
NASH, or nonalcoholic steatohepatitis, is a severe form of nonalcoholic fatty liver disease marked by liver inflammation and damage due to excessive fat accumulation. It is associated with a higher risk of cirrhosis, liver cancer, liver failure, cardiovascular disease, and increased mortality.
Most people with nonalcoholic steatohepatitis (NASH) show no signs or symptoms, but as the condition worsens, they may experience vague symptoms like fatigue, weakness, or abdominal pain. Elevated liver enzymes may be detected in blood tests, although this is not universal among people with NASH.
Nonalcoholic steatohepatitis (NASH) is primarily diagnosed through a liver biopsy, particularly in people who are at risk of advanced liver fibrosis; however, it is often identified incidentally during evaluations for other health issues. Imaging techniques such as ultrasound, CT scans, or specific MRI methods may also be used to detect fat accumulation in the liver.
The primary treatment for nonalcoholic steatohepatitis (NASH) is weight loss through diet and exercise because there are no approved medications specifically for NASH. In severe cases, liver transplantation may be necessary, and vaccinations for hepatitis A and B can help reduce the risk of further liver damage.
Several supplements have been studied for the treatment of nonalcoholic steatohepatitis (NASH), including vitamin E, L-carnitine, betaine, melatonin, silymarin from milk thistle, and various probiotic combinations.
Diet plays a crucial role in managing nonalcoholic steatohepatitis (NASH) by promoting weight loss through a hypocaloric diet, which can reduce liver fat and potentially resolve the condition. Additionally, reducing saturated fat, fructose, and alcohol intake, along with considering other dietary strategies like low-carbohydrate diets or intermittent fasting, may also be beneficial.
Regular physical activity and exercise are recommended for people with nonalcoholic steatohepatitis to aid in weight loss and improve liver health. If diet and exercise alone are not effective, obesity pharmacotherapy and bariatric surgery may be options to consider.
Nonalcoholic steatohepatitis is caused by excessive fat buildup in the liver due to an imbalance between energy intake and expenditure and leads to liver damage and inflammation. People with obesity, metabolic syndrome, and type 2 diabetes are at the highest risk of developing this condition.
Unlock the full potential of Examine
- ^Sheka AC, Adeyi O, Thompson J, Hameed B, Crawford PA, Ikramuddin SNonalcoholic Steatohepatitis: A Review.JAMA.(2020-Mar-24)
- ^Kenneth Cusi, Scott Isaacs, Diana Barb, Rita Basu, Sonia Caprio, W Timothy Garvey, Sangeeta Kashyap, Jeffrey I Mechanick, Marialena Mouzaki, Karl Nadolsky, Mary E Rinella, Miriam B Vos, Zobair YounossiAmerican Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD)Endocr Pract.(2022 May)
- ^Gosalia D, Ratziu V, Stanicic F, Vukicevic D, Zah V, Gunn N, Halegoua-DeMarzio D, Tran TAccuracy of Noninvasive Diagnostic Tests for the Detection of Significant and Advanced Fibrosis Stages in Nonalcoholic Fatty Liver Disease: A Systematic Literature Review of the US Studies.Diagnostics (Basel).(2022-Oct-27)
- ^Westfall E, Jeske R, Bader ARNonalcoholic Fatty Liver Disease: Common Questions and Answers on Diagnosis and Management.Am Fam Physician.(2020-Nov-15)
- ^Victor J Navarro, Steven H Belle, Massimo D'Amato, Nezam Adfhal, Elizabeth M Brunt, Michael W Fried, K Rajender Reddy, Abdus S Wahed, Stephen Harrison, Silymarin in NASH and C Hepatitis (SyNCH) Study GroupSilymarin in non-cirrhotics with non-alcoholic steatohepatitis: A randomized, double-blind, placebo controlled trialPLoS One.(2019 Sep 19)
- ^Chan Wah Kheong, Nik Raihan Nik Mustapha, Sanjiv MahadevaA Randomized Trial of Silymarin for the Treatment of Nonalcoholic SteatohepatitisClin Gastroenterol Hepatol.(2017 Dec)
- ^Carpi RZ, Barbalho SM, Sloan KP, Laurindo LF, Gonzaga HF, Grippa PC, Zutin TLM, Girio RJS, Repetti CSF, Detregiachi CRP, Bueno PCS, Mazuqueli Pereira ESB, Goulart RA, Haber JFDSThe Effects of Probiotics, Prebiotics and Synbiotics in Non-Alcoholic Fat Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH): A Systematic Review.Int J Mol Sci.(2022-Aug-08)
- ^Younossi ZM, Corey KE, Lim JKAGA Clinical Practice Update on Lifestyle Modification Using Diet and Exercise to Achieve Weight Loss in the Management of Nonalcoholic Fatty Liver Disease: Expert Review.Gastroenterology.(2021-02)
- ^Jeffrey W Molloy, Christopher J Calcagno, Christopher D Williams, Frances J Jones, Dawn M Torres, Stephen A HarrisonAssociation of coffee and caffeine consumption with fatty liver disease, nonalcoholic steatohepatitis, and degree of hepatic fibrosisHepatology.(2012 Feb)
- ^Machado MV, Diehl AMPathogenesis of Nonalcoholic Steatohepatitis.Gastroenterology.(2016-Jun)
- ^Spengler EK, Loomba RRecommendations for Diagnosis, Referral for Liver Biopsy, and Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic SteatohepatitisMayo Clin Proc.(2015 Sep)
- Ghrelin - Gonciarz M, Bielański W, Partyka R, Brzozowski T, Konturek PC, Eszyk J, Celiński K, Reiter RJ, Konturek SJPlasma insulin, leptin, adiponectin, resistin, ghrelin, and melatonin in nonalcoholic steatohepatitis patients treated with melatoninJ Pineal Res.(2012 Jun 13)
- Liver Enzymes - Chitapanarux T, Tienboon P, Pojchamarnwiputh S, Leelarungrayub DOpen-labeled pilot study of cysteine-rich whey protein isolate supplementation for nonalcoholic steatohepatitis patientsJ Gastroenterol Hepatol.(2009 Jun)
- Liver Enzymes - T Hasegawa, M Yoneda, K Nakamura, I Makino, A TeranoPlasma transforming growth factor-beta1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: a pilot studyAliment Pharmacol Ther.(2001 Oct)
- Liver Enzymes - Sumida Y, Naito Y, Tanaka S, Sakai K, Inada Y, Taketani H, Kanemasa K, Yasui K, Itoh Y, Okanoue T, Yoshikawa TLong-term (>=2 yr) efficacy of vitamin E for non-alcoholic steatohepatitisHepatogastroenterology.(2013 Sep)
- Liver Enzymes - Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, Neuschwander-Tetri BA, Lavine JE, Tonascia J, Unalp A, Van Natta M, Clark J, Brunt EM, Kleiner DE, Hoofnagle JH, Robuck PR, NASH CRNPioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitisN Engl J Med.(2010 May 6)
- Liver Enzymes - Miwa Kawanaka, Sabina Mahmood, Gouichi Niiyama, Akiyoshi Izumi, Ayumi Kamei, Hideji Ikeda, Mitsuhiko Suehiro, Kazumi Togawa, Takayo Sasagawa, Misako Okita, Hajime Nakamura, Junji Yodoi, Gotaro YamadaControl of oxidative stress and reduction in biochemical markers by Vitamin E treatment in patients with nonalcoholic steatohepatitis: a pilot studyHepatology Research.()
- Liver Enzymes - Chee NM, Sinnanaidu RP, Chan WKVitamin E improves serum markers and histology in adults with metabolic dysfunction-associated steatotic liver disease: Systematic review and meta-analysis.J Gastroenterol Hepatol.(2024 Aug 16)
- Liver Enzymes - Abdelmalek MF, Angulo P, Jorgensen RA, Sylvestre PB, Lindor KDBetaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot studyAm J Gastroenterol.(2001 Sep)
- Liver Enzymes - Sandeep Mukherjee, Tamara Bernard, Kusum Kharbanda, Anthony J. Barak, Michael F. Sorrell, Dean J. TumaImpact of Betaine on Hepatic Fibrosis and Homocysteine in Nonalcoholic Steatohepatitis - A Prospective, Cohort StudyThe Open Translational Medicine Journal.()
- Liver Enzymes - Zhong S, Fan Y, Yan Q, Fan X, Wu B, Han Y, Zhang Y, Chen Y, Zhang H, Niu JThe therapeutic effect of silymarin in the treatment of nonalcoholic fatty disease: A meta-analysis (PRISMA) of randomized control trialsMedicine (Baltimore).(2017 Dec)
- Liver Enzymes - de Avelar CR, Pereira EM, de Farias Costa PR, de Jesus RP, de Oliveira LPMEffect of silymarin on biochemical indicators in patients with liver disease: Systematic review with meta-analysis.World J Gastroenterol.(2017-Jul-21)
- Liver Enzymes - Malaguarnera M, Gargante MP, Russo C, Antic T, Vacante M, Malaguarnera M, Avitabile T, Li Volti G, Galvano FL-carnitine supplementation to diet: a new tool in treatment of nonalcoholic steatohepatitis--a randomized and controlled clinical trialAm J Gastroenterol.(2010 Jun)
- Weight - Amiri-Moghadam S, et alEffects of L-carnitine supplementation on body composition in patients with nonalcoholic steatohepatitis (NASH)CURR TOP NUTRACEUT R.()
- Oxidative Stress Biomarkers - Amiri-Moghadam s, et alEffects of L-carnitine supplementation on inflammatory factors and malondialdehyde in patients with nonalcoholic steatohepatitis (NASH)CURR TOP NUTRACEUT R.()
- Liver Enzymes - Jingwen Zhou, Yidi Chen, Jun Yu, Tianci Li, Ziyu Lu, Yan Chen, Xiaolong Zhang, Fang YeThe efficacy of novel metabolic targeted agents and natural plant drugs for nonalcoholic fatty liver disease treatment: A PRISMA-compliant network meta-analysis of randomized controlled trialsMedicine (Baltimore).(2021 Mar 26)
- Liver Enzymes - Musazadeh V, Assadian K, Rajabi F, Faghfouri AH, Soleymani Y, Kavyani Z, Najafiyan BThe effect of synbiotics on liver enzymes, obesity indices, blood pressure, lipid profile, and inflammation in patients with non-alcoholic fatty liver: A systematic review and meta-analysis of randomized controlled trials.Pharmacol Res.(2024 Sep 4)